Related Experiment Video
Updated: Aug 3, 2025
07:10
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
Published on: April 21, 2019
16.5K
Anti-immunoglobulin E for food allergy.
Jennifer A Dantzer1, Robert A Wood1
1Division of Pediatric Allergy, Immunology, and Rheumatology, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland.
Summary
Anti-immunoglobulin E (IgE) therapies show promise for treating food allergies, potentially improving oral immunotherapy (OIT) outcomes. Ongoing trials investigate these as monotherapy or adjuncts to OIT for conditions like peanut allergy.
Area of Science:
- Immunology
- Allergy and Immunology
- Pharmacology
Background:
- Food allergies are a growing public health concern.
- Current treatments for IgE-mediated food allergy are limited, with oral immunotherapy (OIT) being a primary option.
- Anti-immunoglobulin E (IgE) therapies have emerged as a potential therapeutic strategy.
Purpose of the Study:
- To review the safety and efficacy of anti-IgE therapies for IgE-mediated food allergy.
- To evaluate anti-IgE monotherapy and its use as an adjunct to OIT.
- To discuss ongoing clinical trials and considerations for these emerging treatments.
Main Methods:
- Comprehensive literature searches were conducted in major databases (PubMed, Scopus, etc.).
- Included studies encompassed interventional, observational, and review articles on food allergy and anti-IgE therapies.
- Data from relevant research articles were reviewed and summarized.
Main Results:
- Anti-IgE therapies demonstrate potential in increasing reaction dose thresholds.
- These therapies may reduce the time to reach OIT maintenance and decrease OIT dosing-related reactions.
- Two Phase 3 trials are underway to assess anti-IgE monotherapy for peanut and multifood allergies.
Conclusions:
- Anti-IgE therapies represent a promising advancement in managing IgE-mediated food allergies.
- These treatments may enhance the effectiveness and tolerability of OIT.
- Clinicians should be aware of these novel therapeutic options and ongoing research.
Related Concept Videos
01:10Antibody Structure
60.6K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.6K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
367
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
367
02:06Allergic Reactions
28.0K
Overview
28.0K
01:30Hypersensitivities
844
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
844
01:27Allergic Drug Reactions
905
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
905
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
188
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
188